Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect

BACKGROUND: Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD-1) have significantly improved the outcome of metastasized melanoma and of a rapidly increasing number of other cancer types...

Descripción completa

Detalles Bibliográficos
Autores principales: Boegeholz, J., Brueggen, C. S., Pauli, C., Dimitriou, F., Haralambieva, E., Dummer, R., Manz, M. G., Widmer, C. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155336/
https://www.ncbi.nlm.nih.gov/pubmed/32290812
http://dx.doi.org/10.1186/s12885-020-06763-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155336/
https://www.ncbi.nlm.nih.gov/pubmed/32290812
http://dx.doi.org/10.1186/s12885-020-06763-y

Ejemplares similares